Stereotaxis, Inc. (STXS) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024. Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory, primarily focusing on electrophysiology (cardiac ablation) using its proprietary Robotic Magnetic Navigation (RMN) technology. The company operates as a single segment with sales in the U.S. and internationally.
Key corporate development: On July 31, 2024, Stereotaxis completed the acquisition of Access Point Technologies EP, Inc. (APT), a manufacturer of diagnostic catheters (Map-iT), to enhance in-house catheter development and manufacturing capabilities.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $26.9 million | $26.8 million |
| Gross Margin | $14.6 million (54%) | $14.9 million (56%) |
| Operating Loss | $(24.7) million | $(21.8) million |
| Net Loss | $(24.0) million | $(20.7) million |
| Cash and Cash Equivalents | $12.2 million | $19.8 million |
| Working Capital | $4.8 million | $20.0 million |
| Accumulated Deficit | $(561.7) million | $(537.7) million |
| Backlog (as of Dec 31) | $15.2 million | $14.7 million |
Note: The company reported no debt as of December 31, 2024.
Material Changes vs. Prior Period
- Revenue Stability: Total revenue remained flat (up <1%) due to a slight decrease in system sales ($8.6M vs $8.7M) offset by an increase in disposables, service, and accessories revenue ($18.3M vs $18.0M), driven partially by the APT acquisition.
- Margin Compression: Gross margin percentage decreased from 56% to 54%. This was primarily due to changes in product mix and acquisition-related accounting adjustments requiring the valuation of acquired finished goods inventory to fair value.
- Increased Operating Expenses: General and Administrative (G&A) expenses rose 22% to $17.2 million. This increase was driven by the remeasurement of contingent consideration related to the APT acquisition ($1.8 million charge), higher professional fees, and amortization of acquired intangible assets.
- Liquidity Decline: Cash used in operating activities was $8.5 million. Working capital decreased significantly from $20.0 million to $4.8 million, reflecting the net loss and cash outflows associated with the APT acquisition.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- The company expects approximately 70% of the $15.2 million backlog to be recognized as revenue in 2025.
- Management anticipates continued operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are implemented.
- Regulatory progress includes CE marking for the GenesisX RMN System (Europe) and the MAGiC catheter (Europe), with U.S. FDA clearances pending for several devices.
Key Risks and Contingencies:
- Liquidity Risk: The company has an accumulated deficit of $561.7 million and relies on cash reserves and potential equity/debt financing to fund operations. Management believes current cash is sufficient for at least 12 months.
- Acquisition Integration: Risks associated with integrating APT, including manufacturing complexities and the potential failure to realize anticipated synergies.
- CEO Compensation: A significant portion of operating expenses ($7.2 million in 2024) is attributed to the CEO Performance Share Unit Award, which incurs expense regardless of whether market capitalization milestones are achieved.
- Regulatory and Reimbursement: Delays in FDA approvals for new devices (e.g., MAGiC catheter) or changes in third-party reimbursement policies could materially impact growth.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $12.2 million cash balance against the projected burn rate, given the $24 million net loss and $8.5 million operating cash outflow.
- Backlog Conversion: Monitor the conversion rate of the $15.2 million backlog into recognized revenue in 2025, noting the risks of order cancellations or construction delays.
- APT Integration: Assess the financial performance of the APT subsidiary post-acquisition and the timeline for realizing cost synergies.
- CEO PSU Expense: Review the impact of the $29.8 million remaining unrecognized stock-based compensation expense related to the CEO award on future profitability.
- Regulatory Milestones: Track the status of FDA 510(k) clearances for the GenesisX RMN System and the MAGiC catheter, which are critical for U.S. market expansion.